Literature DB >> 20175958

CD34 expression in glioblastoma and giant cell glioblastoma.

M Galloway1.   

Abstract

OBJECTIVE: This study aimed to determine whether CD34 is expressed in glioblastomas and giant cell glioblastomas, as this information may be of value when attempting to differentiate between giant cell glioblastomas and other relevant differential diagnoses such as pleomorphic xanthoastrocytomas with anaplastic features and anaplastic gangliogliomas. MATERIAL: 11 giant cell glioblastomas and 16 non-giant cell glioblastomas were assessed with immunocytochemical staining for CD34.
METHOD: Standard immunocytochemical techniques were used, to reflect the staining patterns likely to be seen in routine diagnostic practice. Positive staining refers to staining of neoplastic cells.
RESULTS: 73% of giant cell glioblastomas showed some degree of staining for CD34, and 55% showed strong widespread staining. 56% of non-giant cell glioblastomas showed some degree of CD34 staining, and 25% showed strong widespread staining.
CONCLUSIONS: Both giant cell and non-giant cell glioblastomas frequently show CD34 expression by neoplastic cells, which may in some cases be strong and diffuse. Strong widespread staining of neoplastic cells for CD34 was more frequent in giant cell than non-giant cell glioblastomas, however this difference was not statistically significant. CD34 staining in isolation is unlikely to be of assistance in differentiating between giant cell glioblastoma and pleomorphic xanthoastrocytomas with anaplastic features or anaplastic gangliogliomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175958     DOI: 10.5414/npp29089

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  6 in total

1.  Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Authors:  Signe Regner Michaelsen; Thomas Urup; Lars Rønn Olsen; Helle Broholm; Ulrik Lassen; Hans Skovgaard Poulsen
Journal:  J Neurooncol       Date:  2018-01-05       Impact factor: 4.130

2.  ERG is a novel and reliable marker for endothelial cells in central nervous system tumors.

Authors:  Matthew A Haber; Amir Iranmahboob; Cheddhi Thomas; Mengling Liu; Amanda Najjar; David Zagzag
Journal:  Clin Neuropathol       Date:  2015 May-Jun       Impact factor: 1.368

3.  Two cases of multinodular and vacuolating neuronal tumour.

Authors:  Istvan Bodi; Olimpia Curran; Richard Selway; Robert Elwes; Juan Burrone; Ross Laxton; Safa Al-Sarraj; Mrinalini Honavar
Journal:  Acta Neuropathol Commun       Date:  2014-01-20       Impact factor: 7.801

4.  Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway.

Authors:  Jason T Huse; Matija Snuderl; David T W Jones; Carole D Brathwaite; Nolan Altman; Ehud Lavi; Richard Saffery; Alexandra Sexton-Oates; Ingmar Blumcke; David Capper; Matthias A Karajannis; Ryma Benayed; Lukas Chavez; Cheddhi Thomas; Jonathan Serrano; Laetitia Borsu; Marc Ladanyi; Marc K Rosenblum
Journal:  Acta Neuropathol       Date:  2016-11-03       Impact factor: 17.088

5.  IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme.

Authors:  Jiří Polívka; Martin Pešta; Pavel Pitule; Ondřej Hes; Luboš Holubec; Jiří Polívka; Tereza Kubíková; Zbyněk Tonar
Journal:  Oncotarget       Date:  2018-02-20

6.  Multicellular "hotspots" harbor high-grade potential in lower-grade gliomas.

Authors:  Alastair J Kirby; José P Lavrador; Istvan Bodi; Francesco Vergani; Ranjeev Bhangoo; Keyoumars Ashkan; Gerald T Finnerty
Journal:  Neurooncol Adv       Date:  2021-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.